Venus Medtech (Hangzhou) (HKSE:02500) Short-Term Debt & Capital Lease Obligation : HK$541.1 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Venus Medtech (Hangzhou) Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Venus Medtech (Hangzhou)'s Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$541.1 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Venus Medtech (Hangzhou)'s Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$362.6 Mil.

Venus Medtech (Hangzhou) Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Venus Medtech (Hangzhou)'s Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Venus Medtech (Hangzhou) Short-Term Debt & Capital Lease Obligation Chart

Venus Medtech (Hangzhou) Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

143.54

13.15

27.71

274.78

541.09

Venus Medtech (Hangzhou) Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial							27.71	517.92	274.78	384.73	541.09

Venus Medtech (Hangzhou) Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Venus Medtech (Hangzhou) Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Venus Medtech (Hangzhou)'s Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Venus Medtech (Hangzhou) (HKSE:02500) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Venus Medtech (Hangzhou) Inc (HKSE:02500) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

VMTHF:USA

Address

No. 88, Jiangling Road, Room 311, 3rd Floor, Block 2, Binjiang District, Hangzhou, CHN, 310051

Website

https://www.venusmedtech.com

Venus Medtech (Hangzhou) Inc is engaged in the development and commercialization of transcatheter solutions for structural heart diseases. It has two TAVR products on the market, namely VenusA-Valve, and VenusA-Plus. VenusA-Valve is its first-generation TAVR device, which is used to treat severe Aortic Stenosis (AS) using a transcatheter approach. VenusA-Plus is an upgraded product of VenusA-Valve. Geographically all of the revenue is derived from Mainland China.

Executives

Zeng Min Frank	2201 Interest of corporation controlled by you
Zi Zhenjun	2201 Interest of corporation controlled by you
Ming Zhi Investments (bvi) Limited	2101 Beneficial owner
Ming Zhi Investments Limited	2201 Interest of corporation controlled by you
Qiming Venture Partners Iii, L.p.	2201 Interest of corporation controlled by you
Qiming Corporate Gp Iii, Ltd.	2201 Interest of corporation controlled by you
Qiming Gp Iii, L.p.	2201 Interest of corporation controlled by you
Dcp Capital Partners, L.p.	2201 Interest of corporation controlled by you
Dcp General Partner, Ltd	2201 Interest of corporation controlled by you
Dcp, Ltd.	2201 Interest of corporation controlled by you
Liu Haifeng David	2201 Interest of corporation controlled by you
Muheng Capital Partners (hong Kong) Limited	2101 Beneficial owner
Red Giant Limited	2201 Interest of corporation controlled by you
Wolhardt Julian Juul	2201 Interest of corporation controlled by you
Horizon Binjiang Llc	2101 Beneficial owner

Venus Medtech (Hangzhou) (HKSE:02500) Headlines

No Headlines